FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Wong Hing C	Requirir (Month/	2. Date of Event Requiring Statement (Month/Day/Year) 07/19/2021 3. Issuer Name and Ticker or Trading Symbol HCW Biologics Inc. [HCWB]								
(Last) (First) (Middle) C/O HCW BIOLOGICS INC			Relationship of Reporting Person(s) to Issuer (Check all applicable)			to	5. If Amendment, Date of Original Filed (Month/Day/Year)			
2929 N. COMMERCE PARKWAY			X Director X Officer (give title below)			L0% Owner Other (specify pelow)		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting		
(Street) MIRAMAR FL 33025			Chief Executive		· Officer			Person Form filed by More than One Reporting Person		
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			Beneficially Owned (Instr. 4) Form: (D) or		3. Owner Form: Di (D) or Ind (I) (Instr.	irect Owne		ature of Indirect Beneficial ership (Instr. 5)		
Common Stock			4,285,714		D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securit Underlying Derivative Securit 4)		ty (Instr. Conve		ercise	5. Ownership Form:	6. Nature of Indirect Beneficial	
	Date Exercisable	Expiration Date	Title		unt or ber of es	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)	
Series A Redeemable Preferred Stock	(1)	(1)	Common Stock	6,31	6,691 ⁽²⁾	(1)		D		
Series B Redeemable Preferred Stock	(3)	(3)	Common Stock	2,95	4,285 ⁽⁴⁾	(3)		D		
Series C Redeemable Preferred Stock	(5)	(5)	Common Stock	1,07	1,428(6)	(5	5)	D		

Explanation of Responses:

- 1. The Series A Redeemable Preferred Stock is convertible into the issuer's common stock on a one-for-one basis and has no expiration date. It will automatically convert into common stock upon the closing of the issuer's initial public offering.
- 2. Includes 902,977 shares purchased jointly by Hing C. Wong and Bee Yau Huang.
- 3. The Series B Redeemable Preferred Stock is convertible into the issuer's common stock on a one-for-one basis and has no expiration date. It will automatically convert into common stock upon the closing of the issuer's initial public offering.
- ${\it 4. Includes 1,} {\it 525,} {\it 714 shares purchased jointly by Hing C. Wong and Bee Yau Huang.}$
- 5. The Series C Redeemable Preferred Stock is convertible into the issuer's common stock on a one-for-one basis and has no expiration date. It will automatically convert into common stock upon the closing of the issuer's initial public offering.
- 6. Represents shares purchased jointly by Hing C. Wong and Bee Yau Huang.

Remarks:

Exhibit 24.1: Power of Attorney

<u>/s/ Hing C. Wong</u> <u>07/19/2021</u>

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned as a Section 16 reporting person of HCW Biologics Inc. (the "Company"), hereby constitutes and appoints Rebecca Byam and Nicole Valdivieso, and each of them, the undersigned's true and lawful attorney in fact to:

- (1) execute, deliver and file for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney in fact may approve in such attorney in fact's discretion.

The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause

to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys in fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned further acknowledges and agrees that the attorney-in-fact and the Company are relying on written and oral information provided by the undersigned to complete such forms and the undersigned is responsible for reviewing the completed forms prior to their filing. The attorney-in-fact and the Company are not responsible for any errors or omissions in such filings. The attorney-in-fact and the Company are not responsible for determining whether or not the transactions reported could be matched with any other transactions for the purpose of determining liability for short-swing profits under Section 16(b).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys in fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 19th day of July, 2021.

Name: Hing C. Wong